165 related articles for article (PubMed ID: 20870313)
1. Computational structure-activity relationship analysis of small-molecule agonists for human formyl peptide receptors.
Khlebnikov AI; Schepetkin IA; Quinn MT
Eur J Med Chem; 2010 Nov; 45(11):5406-19. PubMed ID: 20870313
[TBL] [Abstract][Full Text] [Related]
2. Identification of novel small-molecule agonists for human formyl peptide receptors and pharmacophore models of their recognition.
Kirpotina LN; Khlebnikov AI; Schepetkin IA; Ye RD; Rabiet MJ; Jutila MA; Quinn MT
Mol Pharmacol; 2010 Feb; 77(2):159-70. PubMed ID: 19903830
[TBL] [Abstract][Full Text] [Related]
3. Gastrin-releasing peptide/neuromedin B receptor antagonists PD176252, PD168368, and related analogs are potent agonists of human formyl-peptide receptors.
Schepetkin IA; Kirpotina LN; Khlebnikov AI; Jutila MA; Quinn MT
Mol Pharmacol; 2011 Jan; 79(1):77-90. PubMed ID: 20943772
[TBL] [Abstract][Full Text] [Related]
4. Development of small molecule non-peptide formyl peptide receptor (FPR) ligands and molecular modeling of their recognition.
Schepetkin IA; Khlebnikov AI; Giovannoni MP; Kirpotina LN; Cilibrizzi A; Quinn MT
Curr Med Chem; 2014; 21(13):1478-504. PubMed ID: 24350845
[TBL] [Abstract][Full Text] [Related]
5. Further studies on 2-arylacetamide pyridazin-3(2H)-ones: design, synthesis and evaluation of 4,6-disubstituted analogs as formyl peptide receptors (FPRs) agonists.
Giovannoni MP; Schepetkin IA; Cilibrizzi A; Crocetti L; Khlebnikov AI; Dahlgren C; Graziano A; Dal Piaz V; Kirpotina LN; Zerbinati S; Vergelli C; Quinn MT
Eur J Med Chem; 2013 Jun; 64():512-28. PubMed ID: 23685570
[TBL] [Abstract][Full Text] [Related]
6. The formyl peptide receptors FPR1 and FPR2 as targets for inflammatory disorders: recent advances in the development of small-molecule agonists.
Yi X; Tran E; Odiba JO; Qin CX; Ritchie RH; Baell JB
Eur J Med Chem; 2024 Feb; 265():115989. PubMed ID: 38199163
[TBL] [Abstract][Full Text] [Related]
7. Novel formyl peptide receptor (FPR) agonists with pyridinone and pyrimidindione scaffolds that are potentially useful for the treatment of rheumatoid arthritis.
Crocetti L; Vergelli C; Guerrini G; Cantini N; Kirpotina LN; Schepetkin IA; Quinn MT; Parisio C; Di Cesare Mannelli L; Ghelardini C; Giovannoni MP
Bioorg Chem; 2020 Jul; 100():103880. PubMed ID: 32388428
[TBL] [Abstract][Full Text] [Related]
8. 3-(1H-indol-3-yl)-2-[3-(4-nitrophenyl)ureido]propanamide enantiomers with human formyl-peptide receptor agonist activity: molecular modeling of chiral recognition by FPR2.
Schepetkin IA; Kirpotina LN; Khlebnikov AI; Leopoldo M; Lucente E; Lacivita E; De Giorgio P; Quinn MT
Biochem Pharmacol; 2013 Feb; 85(3):404-16. PubMed ID: 23219934
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of Five- and Six-Membered N-Phenylacetamido Substituted Heterocycles as Formyl Peptide Receptor Agonists.
Vergelli C; Schepetkin IA; Ciciani G; Cilibrizzi A; Crocetti L; Giovannoni MP; Guerrini G; Iacovone A; Kirpotina LN; Ye RD; Quinn MT
Drug Dev Res; 2017 Feb; 78(1):49-62. PubMed ID: 27859446
[TBL] [Abstract][Full Text] [Related]
10. Molecular docking of 2-(benzimidazol-2-ylthio)-N-phenylacetamide-derived small-molecule agonists of human formyl peptide receptor 1.
Khlebnikov AI; Schepetkin IA; Kirpotina LN; Brive L; Dahlgren C; Jutila MA; Quinn MT
J Mol Model; 2012 Jun; 18(6):2831-43. PubMed ID: 22127612
[TBL] [Abstract][Full Text] [Related]
11. Peptide length and folding state govern the capacity of staphylococcal β-type phenol-soluble modulins to activate human formyl-peptide receptors 1 or 2.
Kretschmer D; Rautenberg M; Linke D; Peschel A
J Leukoc Biol; 2015 Apr; 97(4):689-97. PubMed ID: 25724390
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, biological evaluation, molecular modeling, and structural analysis of new pyrazole and pyrazolone derivatives as N-formyl peptide receptors agonists.
Vergelli C; Khlebnikov AI; Crocetti L; Guerrini G; Cantini N; Kirpotina LN; Schepetkin IA; Cilibrizzi A; Quinn MT; Rossi P; Paoli P; Giovannoni MP
Chem Biol Drug Des; 2021 Oct; 98(4):582-603. PubMed ID: 34148303
[TBL] [Abstract][Full Text] [Related]
13. 2-Arylacetamido-4-phenylamino-5-substituted pyridazinones as formyl peptide receptors agonists.
Vergelli C; Schepetkin IA; Ciciani G; Cilibrizzi A; Crocetti L; Giovannoni MP; Guerrini G; Iacovone A; Kirpotina LN; Khlebnikov AI; Ye RD; Quinn MT
Bioorg Med Chem; 2016 Jun; 24(11):2530-2543. PubMed ID: 27134116
[TBL] [Abstract][Full Text] [Related]
14. Molecular recognition of formylpeptides and diverse agonists by the formylpeptide receptors FPR1 and FPR2.
Zhuang Y; Wang L; Guo J; Sun D; Wang Y; Liu W; Xu HE; Zhang C
Nat Commun; 2022 Feb; 13(1):1054. PubMed ID: 35217703
[TBL] [Abstract][Full Text] [Related]
15. Unleashing the power of formyl peptide receptor 2 in cardiovascular disease.
Prevete N; Poto R; Marone G; Varricchi G
Cytokine; 2023 Sep; 169():156298. PubMed ID: 37454543
[TBL] [Abstract][Full Text] [Related]
16. Structural changes of the ligand and of the receptor alters the receptor preference for neutrophil activating peptides starting with a formylmethionyl group.
Forsman H; Winther M; Gabl M; Skovbakke SL; Boulay F; Rabiet MJ; Dahlgren C
Biochim Biophys Acta; 2015 Jan; 1853(1):192-200. PubMed ID: 25447672
[TBL] [Abstract][Full Text] [Related]
17. The formyl peptide receptor 1 exerts a tumor suppressor function in human gastric cancer by inhibiting angiogenesis.
Prevete N; Liotti F; Visciano C; Marone G; Melillo RM; de Paulis A
Oncogene; 2015 Jul; 34(29):3826-38. PubMed ID: 25263443
[TBL] [Abstract][Full Text] [Related]
18. A non-peptide receptor inhibitor with selectivity for one of the neutrophil formyl peptide receptors, FPR 1.
Cevik-Aras H; Kalderén C; Jenmalm Jensen A; Oprea T; Dahlgren C; Forsman H
Biochem Pharmacol; 2012 Jun; 83(12):1655-62. PubMed ID: 22410002
[TBL] [Abstract][Full Text] [Related]
19. The formyl peptide receptor agonist FPRa14 induces differentiation of Neuro2a mouse neuroblastoma cells into multiple distinct morphologies which can be specifically inhibited with FPR antagonists and FPR knockdown using siRNA.
Cussell PJG; Howe MS; Illingworth TA; Gomez Escalada M; Milton NGN; Paterson AWJ
PLoS One; 2019; 14(6):e0217815. PubMed ID: 31170199
[TBL] [Abstract][Full Text] [Related]
20. Formyl peptide receptor 2 is an emerging modulator of inflammation in the liver.
Lee C; Han J; Jung Y
Exp Mol Med; 2023 Feb; 55(2):325-332. PubMed ID: 36750693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
